[Sulglycotide combined with H2-antagonists in the prevention of duodenal ulcer recurrence. Multicenter study].
The aim of the present study was to evaluate the role of sulglycotide, a molecule with gastroprotective properties, in monotherapy and in association with H2-antagonists in the maintenance treatment of duodenal ulcer. The study was performed using a fully randomized experimental design. Following endoscopic confirmation, 626 patients with healed duodenal ulcer were treated for 6 months with sulglycotide 200 mg tid (293 patients) or sulglycotide + H2-antagonists (333 patients). After 2, 4 and 6 months patients underwent a clinical control whereas an endoscopic control was performed after 6 months. The cumulative percentage of recidivation was 3.6% in the sulglycotide + H2-antagonist treated group, whereas the group treated with sulglycotide alone showed a recidivation rate of 15.4% (p < 0.001). These findings suggest the utility of combined sulglycotide and H2-antagonist treatment in the maintenance therapy for duodenal ulcer.
Ciaco
A
A
Servizio di Gastroenterologia ed Endoscopia Digestiva, Ospedale S. Filippo Neri, Roma.
Papi
C
C
Capurso
L
L
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000517:prevention & control*; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012795:Sialoglycoproteins / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D012795:Sialoglycoproteins; C009354:sulglicotide
Sulglicotide in associazione agli H2-antagonisti nella prevenzione della recidiva ulcerosa duodenale. Studio multicentrico.